Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15232, USA.
University of Pittsburgh, Melanoma Center, UPMC Hillman, Suite L1.32c Hillman Research Pavilion, 5117 Centre Avenue, Pittsburgh, PA 15232, USA.
Hematol Oncol Clin North Am. 2021 Feb;35(1):1-27. doi: 10.1016/j.hoc.2020.09.003. Epub 2020 Oct 26.
The management of melanoma significantly improved within the last 25 years. Chemotherapy was the first approved systemic therapeutic approach and resulted in a median overall of survival less than 1 year, without survival improvement in phase III trials. High-dose interferon α2b and IL-2 were introduced for resectable high-risk and advanced disease, respectively, resulting in improved survival and response rates. The anti-CTLA4 and anti-programmed death 1 monoclonal antibodies along with BRAF/MEK targeted therapies are the dominant therapeutic classes of agent for melanoma. This article provides an historic overview of the evolution of melanoma management.
在过去的 25 年中，黑色素瘤的治疗取得了显著进展。化疗是第一种被批准的全身性治疗方法，但在 III 期临床试验中并未改善患者的总生存时间，中位总生存期不足 1 年。高剂量干扰素 α2b 和白细胞介素 2 分别用于可切除的高危和晚期疾病，可改善生存和缓解率。抗 CTLA4 和抗程序性死亡 1 单克隆抗体以及 BRAF/MEK 靶向治疗是黑色素瘤的主要治疗药物类别。本文对黑色素瘤治疗的发展历程进行了历史性回顾。
